期刊文献+

胃神经内分泌肿瘤的临床病理组织学特点及预后分析 被引量:4

Clinical and Histopathological Characteristics and Prognosis of Patients with Gastric Neuroendocrine Tumors
在线阅读 下载PDF
导出
摘要 目的分析胃神经内分泌肿瘤患者的病理组织学特点,为临床上其诊治提供参考。方法对经胃镜取病理组织学检查或术后行病理检查确诊为胃神经内分泌肿瘤的136例患者的临床资料进行回顾性分析。结果胃神经内分泌肿瘤的临床表现以上腹部不适或疼痛为多(66.9%),肿瘤均为单发性,其部位分布为:贲门部48例、胃体部47例、胃窦部21例、胃底8例、胃角部12例。肿瘤大体形态有溃疡型118例、息肉型18例。胃神经内分泌瘤17例,其中G_1级9例,G2级8例;胃神经内分泌癌119例,全部为G_3级。随访患者1、3、5年生存率分别为84.8%、50.2%、40.8%。结论胃神经内分泌肿瘤患者的预后与肿瘤病理类型、有无淋巴结或远处转移密切相关。 Objective To analyze the clinical and histopathological characteristics and prognosis of the patients with gastric neuroendocrine tumors,and provide reference for clinical diagnosis and treatment. Methods Clinical data of 136 patients confirmed to be gastric neuroendocrine tumors by gastroscopic histological examination or pathological examination after operation were retrospectively analyzed. Results Clinical manifestations of gastric neuroendocrine tumors were mainly abdominal discomfort or pain( 66. 9%),tumor were all single,the distribution were as follows: the cardia 48 cases,gastric body 47 cases,gastric antrum 21 cases,stomach bottom 8 cases,and gastric angle 12 cases. Tumor gross morphology included ulcer type 118 cases,and polyp type 18 cases. Among 17 cases of patients with gastric neuroendocrine tumors,there were 9 cases of G_1 stage and 8 cases of G_2 stage,119 cases of gastric neuroendocrine carcinoma were all G_3 stage. The 1-,3-,5-year survival rates were 84. 8%,50. 2%,40. 8%,respectively. Conclusion The prognosis of patients with gastric neuroendocrine tumors are closely related with tumor pathological type,the presence of lymph node or distant metastasis.
出处 《实用癌症杂志》 2016年第5期790-792,共3页 The Practical Journal of Cancer
关键词 胃神经内分泌瘤 病理组织学 预后 Gastric neuroendocrine tumors Histopathology Prognosis
  • 相关文献

参考文献4

二级参考文献103

  • 1杨爱明,陆星华,钱家鸣,刘晓红,鲁重美.超声内镜在胰岛细胞瘤定位诊断中的作用[J].中华消化内镜杂志,2006,23(3):169-171. 被引量:17
  • 2Yaov JC,Hassan M,Phan A,et al.One hundred years after "carcinoid ":epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.J Clin Oncol,2008,26(18):3063-3072.
  • 3Yao JC,Shah MH,Ito T,et al.Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med,2011,364(6):514-523.
  • 4Raymond E,Dahan L,Raoul JL,et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.N Engl J Med,2011,36(6):501-513.
  • 5Kl(o)ppel G,Couvelard A,Perren A,et al.ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification.Neuroendocrinology,2009,90 (2):162-166.
  • 6Klimstra DS,Modlin IR,Adsay NV,et al.Pathology reporting of neuroendocrine tumors:application of the Delphic consensus process to the development of a minimum pathology data set.Am J Surg Pathol,2010,34(3):300-313.
  • 7Bosman FT,Carneiro F,Hruban RH,et al.WHO classification of tumours of the digestive system.Lyon:IARC Press,2010.
  • 8Oberndorfer S.Karzinoide tumoren des dunndarms.Frankf ZPatrol,1907,1:426-432.
  • 9Williams ED,Siebenmann RE,Sobin LH.Histological typing of endocrine tumours.Geneva:World Health Organization,1980.
  • 10Hamilton SR,Aaltonen LA.World Health Organization classification of tumours.Pathology and genetics of tumours of the digestive system.Lyon:IARC Press,2000.

共引文献452

同被引文献20

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部